ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00539.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:Defective iron metabolism, mild haemolysis and impaired erythropoiesis contribute to the anaemia of chronic disorders (ACD), but evidence for a deficiency of circulating erythropoietin (Epo) is equivocal. We have examined serum Epo in moderately anaemic patients with Hb<10 g/dl — 41 patients with ACD (23 associated with rheumatoid disease and 18 with malignancy), 17 with uncomplicated iron‐deficiency anaemia and 33 with chronic renal failure (CRF). In ACD the serum Epo (mean (confidence limits)) results of 41 (31, 54) mU/ml for the rheumatoid group and 63 (49, 80) mU/ml for the malignancy group, were significantly lower than the Epo of 104 (78, 136) mU/ml for the iron‐deficiency group. The CRF group with more severe anaemia had serum Epo of 27 (19, 35)mU/ml. Thus, recombinant human erythropoietin (rHu Epo) should be considered for the treatment of ACD associated with rheumatoid disease and malig

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00540.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:52 patients with CLL, presenting primarily with splenomegaly, stage II‐IV according to the Rai stage system, were treated with a regime of low‐dose splenic irradiation (SI) between January, 1979 and December 1987. The treatment modality consisted of 1 Gy, from 1 to 10 doses, given at weekly intervals. The median given dose was 700 cGy (100–1000). CHR occurred in 23/52 (44%), PR in 20/52 (38%) and no reponse (NR) in 9/52 (17%) of the patients. The median duration of remission was 9 months (range 3–24), 15 and 7 months for patients achieving CHR and PR, respectively. At relapse, 14 patients received a second course of SI by the same modalities: 2 ot them obtained a second CHR, 9 a PR and 3 NR. The median duration of remission was 4 months. In conclusion, SI represents a suitable therapy for CLL patients presenting primarily with splenomegaly. The low rate of response and the short remission duration after the second treatment suggest that SI should be combined either with splenectomy or with other therapeutic app

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00541.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:Gliotoxin, an epipolythiodioxopiperazine, is a fungal metabolite that causes genomic DNA degradation preferentially in certain blood cell types including T lymphocytes and macrophages. Gliotoxin has previously been used to treat murine allogeneic bone marrow prior to transplantation into irradiated recipients, and in this situation the drug prevents development of graft‐versus‐host disease, and permits the establishment of allogeneic bone marrow chimeras. We have examined the nature of the cells that survive gliotoxin treatment and report here that gliotoxin selectively spares a unique class of haemopoietic stem cell that forms large (HPP) colonies in the presence of mixtures of M‐CSF and IL‐3. We confirm that the cells which survive gliotoxin treatment are capable of reconstituting the haemopoietic system in allogeneic lethally irradiat

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00542.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:The aim of the present study was to test the effect of cyclosporin A (CyA)in vitroon CFU‐GM growth from patients with severe aplastic anemia (SAA). For this purpose, bone marrow (BM) cells from 9 SAA patients and 5 healthy individuals were incubated with or without CyA and then cultured for CFU‐GM growth in the presence of exogenous recombinant human GM‐CSF (30 ng/ml). SAA patients were tested before or after treatment with CyA, or after treatment with antilymphocyte globulin (ALG). In 3 patients responding to CyA, the addition of CyAin vitroenhanced colony growth from 13 ± 10 to 40 ± 20/105BM cells (p = 0.01) — the median increment of colony formation was 2.4‐fold. In 5 ALG responders, CyA produced no increment of CFU‐GM growth (from 14 ± 26 to 15 ± 16/105BM cells, p = 0.1). CyA did not enhance significantly CFU‐GM growth in normal controls (from 57 ± 45 to 58 ± 81/105BM cells, p = 0.9). In conclusion, it would appear that some patients with SAA can respond to CyAin vivoandin vitro, and ALG responders are not necessarily among these. This is in keeping with different mechanisms of action of CyA and ALG and possibly with the existence of distinct pathogene

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00543.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:Fatal “postoperative erythroderma” (POE) developed in 2 patients treated with liver lobectomy and the transfusion of fresh blood. Their clinical features and skin‐histological findings were indicative of acute graft‐versus‐host disease (GVHD). The HLA phenotypes of circulating lymphocytes of the 2 patients were heterozygous but became homozygous late in the clinical course and were identical with those of the blood donors. One of the patient's haplotypes was identical with the donor's homozygous haplotype. These findings suggest the mechanism of development of POE in apparently immunocompetent patients. The donor's T lymphocytes are histocompatible with the patient's tissues, are not rejected, and become engrafted. The patient's tissues are not histocompatible with the donor's, so that GVHD

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00544.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:Human granulocyte colony‐stimulating factor (G‐CSF) receptors on human acute leukemia cells were investigated using human G‐CSF iodolabeled by the lactoperoxidase method. Among various human leukemic cell lines, only cells of myelogenous lineage including HL‐60, THP‐1 and U937 had one type of high‐affinity receptor for G‐CSF, as shown by Scatchard analysis. Fresh leukemia cells from 19 patients with acute myelogenous leukemia (AML) were then studied. Specific receptors for G‐CSF were demonstrated on blast cells in all 19 cases, the mean number of G‐CSF receptors per AML cell ranging from 95 to 1436. G‐CSF receptors on AML cells appeared to be a single affinity type, although some variations were observed. The mean number of G‐CSF receptors on leukemic cells from patients with either FAB M3 or FAB M2 was greater than that of cells from patients with Ml (p<0.01, p<0.10, respectively). Moreover, the mean number of receptors for G‐CSF on CD13‐and CD34‐positive AML cells was higher than that on CD13‐negative and CD34‐positive AML cells (p<0.01), and the mean number of G‐CSF receptors on CD7‐positive AML cells was lower than that for CD7‐negative AML cells (p<0.10). Since the FAB classification and surface phenotypes reflect maturation stages, our findings indicate that the distribution of G‐CSF receptors, even on AML cells, m

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00545.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:Recombinant human IFN‐γ (100–1000 U/ml) inhibited the IL‐6‐induced growth of 2 human IL‐6‐dependent multiple myeloma (MM) cell lines U‐1958 and U‐266–1970in vitro. In contrast, the U‐1996 line, independent of IL‐6 for maintenance at a slow growth rate but responding to IL‐6 by increased proliferation, and the IL‐6‐independent U‐266–1984 were refractory to the anti‐proliferative effect of IFN‐γ. The effect of IFN‐γ in the sensitive MM cell lines was cytostatic in U‐266–1970, and cytostatic and cytotoxic in U‐1958. Northern blot analysis revealed that the growth inhibition of the IL‐6‐dependent MM cell line U‐1958 was not due to down‐regulation of IL‐6 receptor mRNA expression and that the differential sensitivity to IFN‐γ was not due to differences in IFN‐γ receptor expression. The growth inhibition was not a consequence of an IFN‐γ‐induced terminal differentiation as flow cytometric analyses demonstrated an arrest in all phases of the cell cycle. IFN‐α inhibited the growth in 3 of the 4 cell lines tested. The results thus suggest that the particular MM phenotype, which includes IL‐6 dependency for survival and growth, may also be characterized by IFN‐γ sensitivity. Furthermore, the study demonstrates that MM cell lines are not simultaneously sensitive to IFN‐γ and α

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00546.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

摘要:

Abstract:113 patients with acute myelogenous leukemia (AML), representing 82% of the total cohort of AML patients within the geographical area of northern Sweden, were recorded. The total complete remission (CR) rate was 47.8 %, and median survival was 4 months. The probability of long‐term survival for all patients without exclusions was only 5%. Thus, the results from this study differ strongly from data on patient outcome in most therapy studies in AML, where the influence of patient selection on the results is larger. The median age in our patients was 63 years, which is also higher than in most other studies. Elderly patients had a low CR rate (24% in patients>70 yr), but remission duration was similar in the different age groups. Patients treated according to “high‐dose” protocols had a CR rate of 64%, while only 14% of less aggressively treated patients achieved remission. A better response rate after more aggressive chemotherapy was evident also in elderly patients. CR rate was 81% in patients below 60 yr of age who had no antecedent blood disorder and who had had symptoms for less than 3 months. Other variables with prognostic implications were: cytogenetic subgroup, antecedent hematological disease, and level of serum ferritin. High serum ferritin was associated with short CR duration. Ferritin is produced by the leukemic cells and could be regarded as a marker for leukemic a

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00547.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1991.tb00548.x

出版商:Blackwell Publishing Ltd    

年代:1991

数据来源: WILEY